Aga institute
Consensus Development Conference on the Use of Nonsteroidal Anti-Inflammatory Agents, Including Cyclooxygenase-2 Enzyme Inhibitors and Aspirin

https://doi.org/10.1016/j.cgh.2006.04.010Get rights and content

Section snippets

Background

Nonsteroidal anti-inflammatory drugs (NSAIDs) are among the most commonly used medications in the world. Well-recognized gastrointestinal (GI) complications and identification of previously unrecognized cardiac risks have amplified concerns about their use. The extent of these risks varies by patient, specific agent, dosage, and concomitant medications. To increase awareness about the benefits and the risks of gastrointestinal toxicity and myocardial infarction associated with these medications

First page preview

First page preview
Click to open first page preview
View PDF

References (101)

  • W.A. Ray et al.

    Nonsteroidal anti-inflammatory drugs and risk of serious coronary heart disease: an observational cohort study

    Lancet

    (2002)
  • D.J. Graham et al.

    Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study

    Lancet

    (2005)
  • R. Collins et al.

    Blood pressure, stroke, and coronary artery diseasePart 2: short-term reductions in blood pressure: overview of randomized drug trials in their epidemiological context

    Lancet

    (1990)
  • D.A. Corley et al.

    Protective association of ASA/NSAIDs and esophageal cancer: a systematic review and meta-analysis

    Gastroenterology

    (2003)
  • T.M. MacDonald et al.

    Effect of ibuprofen on cardioprotective effect of ASA

    Lancet

    (2003)
  • F.K. Chan et al.

    Eradication of Helicobacter pylori and risk of peptic ulcers in patients starting long-term treatment with non-steroidal anti-inflammatory drugs: a randomised trial

    Lancet

    (2002)
  • C.J. Hawkey et al.

    Randomised controlled trial of Helicobacter pylori eradication in patients on non-steroidal anti-inflammatory drugs: HELP NSAIDs studyHelicobacter Eradication for Lesion Prevention

    Lancet

    (1998)
  • H.T. Sørensen et al.

    Risk of upper gastrointestinal bleeding associated with use of low-dose aspirin

    Am J Gastroenterol

    (2000)

  • Bayer Pharmaceuticals

    (2003)
  • A.C. Phillips et al.

    NSAIDs and the elderly: toxicity and the economic implications

    Drugs Aging

    (1997)
  • T. Pincus et al.

    A randomized, double-blind, crossover clinical trial of diclofenac plus misoprostol versus acetaminophen in patients with osteoarthritis of the hip or knee

    Arthritis Rheum

    (2001)
  • T. Pincus et al.

    Patient preference for placebo, acetaminophen or celecoxib efficacy studies (PACES): two randomized placebo-controlled cross-over clinical trials in patients with osteoarthritis of the knee or hip

    Ann Rheum Dis

    (2004)
  • J.P. Case et al.

    Lack of efficacy of acetaminophen in treating symptomatic knee osteoarthritis: a randomized, double-blind, placebo-controlled comparison trial with diclofenac sodium

    Arch Intern Med

    (2003)
  • F. Catella-Lawson et al.

    Cyclooxygenase inhibitors and the antiplatelet effects of ASA

    N Engl J Med

    (2001)
  • F.E. Silverstein et al.

    Gastrointestinal toxicity with celecoxib vs. nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trialCelecoxib Long-Term Arthritis Safety Study

    JAMA

    (2000)
  • C. Bombardier et al.

    Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis

    N Engl J Med

    (2000)
  • D. Ramosekh et al.

    Outcome of peptic ulcer bleeding, nonsteroidal anti-inflammatory drug use and Helicobacter pylori infection

    Clin Gastroenterol Hepatol

    (2005)

  • Physician’s desk reference

    (2005)
  • G. Singh et al.

    NSAID induced gastrointestinal complications: the ARAMIS perspective

    J Rheumatol

    (1998)
  • A. Lanas et al.

    A nationwide study of mortality associated with hospital admission due to severe gastrointestinal events and those associated with non-steroidal anti-inflammatory drug use

    Am J Gastroenterol

    (2005)
  • B. Cryer

    NSAID-associated death: the rise and fall of NSAID-associated GI mortality

    Am J Gastroenterol

    (2005)
  • J.F. Fries et al.

    The rise and decline of nonsteroidal drug-associated gastropathy in rheumatoid arthritis

    Arthritis Rheum

    (2004)
  • F.E. Silverstein et al.

    Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs: a randomized, double-blind, placebo-controlled trial

    Ann Intern Med

    (1995)
  • M.R. Griffin et al.

    Nonsteroidal anti-inflammatory drug use and increased risk for peptic ulcer disease in elderly persons

    Ann Intern Med

    (1991)
  • S.E. Gabriel et al.

    Risk for serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs

    Ann Intern Med

    (1991)
  • L.A. Garcia Rodriguez et al.

    Relative risk of upper gastrointestinal complications among users of acetaminophen and nonsteroidal anti-inflammatory drugs

    Epidemiology

    (2001)
  • S. Hernandez-Diaz et al.

    Association between nonsteroidal anti-inflammatory drugs and upper gastrointestinal tract bleeding/perforation: an overview of epidemiologic studies published in the 1990s

    Arch Intern Med

    (2000)
  • F.J. de Abajo et al.

    Risk of upper gastrointestinal bleeding and perforation associated with low-dose aspirin as plain and enteric-coated formulations

    BMC Clin Pharmacol

    (2001)
  • L.S. Simon et al.

    Nonsteroidal anti-inflammatory drugs

    N Engl J Med

    (1980)
  • C.M. Wilcox et al.

    Striking prevalence of over-the-counter nonsteroidal anti-inflammatory drug use in patients with upper gastrointestinal hemorrhage

    Arch Intern Med

    (1994)
  • J.M. Piper et al.

    Corticosteroid use and peptic ulcer disease: role of nonsteroidal anti-inflammatory drugs

    Ann Intern Med

    (1991)
  • L.A.G. Rodriquez et al.

    Risk of upper gastrointestinal bleeding and perforation associated with individual non-steroidal anti-inflammatory drugs

    Lancet

    (1994)
  • D.A. Peura et al.

    The American College of Gastroenterology Bleeding Registry: preliminary findings

    Am J Gastroenterol

    (1997)
  • J. Weil et al.

    Prophylactic aspirin and risk of peptic ulcer bleeding

    BMJ

    (1995)
  • Y. Niv et al.

    Endoscopy in asymptomatic minidose ASA consumers

    Dig Dis Sci

    (2005)
  • S. Derry et al.

    Risk of gastrointestinal haemorrhage with long-term use of ASA: meta-analysis

    BMJ

    (2000)
  • L.S. Simon et al.

    The Anti-inflammatory and Upper Gastrointestinal Effects of Celecoxib In Rheumatoid Arthritis: a randomized, controlled trial

    JAMA

    (1999)
  • R.S. Bresalier et al.

    for the Adenomatous Polyp Prevention on Vioxx (APPROVe) Trial InvestigatorsCardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial

    N Engl J Med

    (2005)

  • FDA Arthritis Advisory Committee Hearing

    (2001)
  • S.D. Solomon et al.

    for the Adenoma Prevention with Celecoxib (APC) Study InvestigatorsCardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention

    N Engl J Med

    (2005)

    • Cited by (0)

    A list of the Consensus Development Panel and Speakers may be viewed online at www.cghjournal.org.

    Byron Cryer has served as a Consultant to AstraZeneca, TAP Pharmaceuticals, and Pfizer, Inc. Richard Hunt discloses having been a Consultant at some time to Merck, Pfizer, Novartis, AstraZeneca, TAP, Santarus, and Altana, and a past investigator for Merck, Novartis, AstraZeneca, TAP, and Altana. Angel Lanas has received grants and travel support from AstraZeneca, Takeda, and Pfizer, and he is a Board Member of the APPROVE Trial by Merck & Company. Harold Paulus has had no financial conflicts of interest in the past 3 years, although he has prior consultancies with many pharmaceutical companies. Robert S. Sandler is a Consultant to Merck, Bayer, Takeda, and GlaxoSmithKline, and has received grant support from Merck. Lee Simon has received speaking honoraria from Academy of Healthcare, Pfizer, Avanir, and the Foundation for Better Healthcare, and he has been a Consultant to AstraZeneca, Cerimon, Alpha Rx, Proprius, Avanir, Novartis, Pfizer, Aldolor, Paraexel, Affinergy, Aai pharma, Alder, Cell Therapeutics, Altea, Chelsea Pharmaceuticals, Cure, Coley, Puretech Ventures, Solace Pharmaceuticals, Nuvo, Dr Reddy’s, Genelabs, Jazz, Medimmune, Neopharm, Neuromed, Nitec, Nomura Ventures, Purdue, Sepracor, Serono, Savient, Polymerix, Rigel, Roche, TAP, and Zydus.

    View full text
    Copyright © 2006 American Gastroenterological Association. Published by Elsevier Ltd. All rights reserved.